Biotech News
Related news
GRIGRI Bio2026-06-18 13:31 EST
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRIGRI Bio2026-08-24 14:05 EST
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
IMMPImmutep Limited2026-07-24 12:00 EST
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
AVTXAvalo Therapeutics2026-07-22 11:00 EST
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
KNSAKiniksa2026-08-07 20:01 EST
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
KNSAKiniksa2026-05-29 20:01 EST
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
EQEquillium, Inc.2026-05-28 20:05 EST
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
TLSATiziana Life Sciences2026-05-28 11:00 EST
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
XGNExagen2026-07-28 13:00 EST
Exagen Inc. to Participate in Upcoming Investor Conference
GRI Bio
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.
Recent company news
GRIGRI Bio2026-08-24 14:05 EST
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
GRIGRI Bio2026-06-18 13:31 EST
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRIGRI Bio2026-05-14 13:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRIGRI Bio2026-05-14 13:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRIGRI Bio2026-05-14 08:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Stock data
- Close
- 1.65 USD
- Market cap
- 3.56M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States